Who Takes the Mushrooms

Here's who's taking the mushrooms: young adults (18-25), non-Hispanic white, college-educated, earning between $20,000 and $75,000 or above it, and almost certainly already using cannabis — which predicts psilocybin use at 13 times higher odds than baseline. People experiencing depression show higher rates too, though researchers were careful to note the causality runs in both directions.

Here's who's not: Black and Hispanic Americans, high school dropouts, people earning under $20,000.

The researchers wanted demographics. What they got is a map of access. Not just legal or physical access — social access. The psychedelic renaissance isn't distributing itself evenly. It's following the same gradient every wellness intervention follows when it moves from counterculture to mainstream: it lands first among the people already comfortable with the vocabulary.

That cannabis number is the key to reading this clearly. This isn't primarily a story about desperate patients accessing relief through clinical psilocybin programs. It's about people who already know what it feels like to alter their consciousness deliberately, for whom adding mushrooms is less a leap than a step. The gateway isn't spiritual seeking or clinical need. The gateway is familiarity with bending your mind safely — and the social permission to do it.

The substance hasn't changed. Humans have been ingesting psilocybin mushrooms for roughly 10,000 years. What's changed is the story we tell about who's holding them. In the 1970s: dangerous. In the 1990s: Schedule I, no accepted medical use. In 2025: published in The American Journal of Psychiatry, discussed in weekend magazine features, pending FDA approval for therapeutic use. The envelope of culturally acceptable consciousness-expansion is moving.

The uncomfortable question the demographics pose is who moves inside that envelope, and who gets left outside it.

Medicalization is genuinely promising — there's real evidence for treatment-resistant depression. But medicalization follows power gradients. It always has. The people already most likely to use psilocybin recreationally are the same people most likely to have insurance that covers experimental treatment, therapists who know about the clinics, and enough cultural capital to be perceived as "treating depression" rather than "doing drugs."

The substance is the same in both cases. The story isn't.

What the survey can't capture is who's using it without showing up in federal data: communities where psilocybin was never counterculture because it was always Indigenous practice, and people who use quietly, away from the permission structures that make 8 million Americans comfortable enough to admit it to a government survey.

2.8% told the truth. The actual number is almost certainly larger, and more evenly distributed, than the data suggests.

The psychedelic renaissance is real. The question worth sitting with is whether what's new is the consciousness-expansion, or just who gets credit for it.